View Older Stories View More Recent Stories
-
Here's the list of top biotech stocks to own for 2026
-
Amgen expands direct-pay program, cuts drug prices up to 80%
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
Trump to announce prescription drug price agreements
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
Oppenheimer Upgrades Amgen (AMGN) to Outperform
-
Amgen (AMGN) Declares $2.52 Quarterly Dividend; 3.2% Yield
-
Erste Group Upgrades Amgen (AMGN) to Buy
-
Amgen (AMGN) PT Raised to $372 at BMO Capital
-
Bernstein on IRA pricing: $245 really is the floor
-
Goldman Sachs Reiterates Buy Rating on Amgen (AMGN)
-
FDA grants full approval for Amgen's IMDELLTRA in lung cancer
-
Amgen (AMGN) PT Raised to $381 at Piper Sandler
-
Amgen (AMGN) PT Raised to $315 at Cantor Fitzgerald
-
Piper Sandler on Amgen (AMGN): 'Continued Strong Commercial Execution Across The Board'
-
Baird Reiterates Underperform Rating on Amgen (AMGN), '3Q25 Financials Look Mostly Solid'
-
Amgen (AMGN) Tops Q3 EPS by 60c, Offers Guidance
-
Amgen is due to report after the bell on Tuesday. Here's what to watch out for.
-
Amgen (AMGN) call put 1.6 calls to 1 put into quarter results
-
Amgen (AMGN) Declares $2.38 Quarterly Dividend; 3.2% Yield
-
ExxonMobil elects Gregory Garland to board of directors
-
Tezspire wins EU approval for chronic rhinosinusitis with nasal polyps
-
AstraZeneca's Tezspire gets FDA approval for nasal polyp condition
-
AMGEN launches direct-to-patient program for cholesterol drug
-
Bernstein: Positive VESALIUS-CV Data Is 'Great News for Amgen (AMGN)'
-
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)
-
Amgen (AMGN) 30-day option implied volatility flat
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Amgen plans $650 million manufacturing expansion, creating 750 jobs
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
-
Regeneron (REGN) See Strength Following Opening Bell Weakness, Now up Over 2pct
-
Regeneron (REGN) Shares Decline on the Open
-
Raymond James Comments on REGN and AMGN Earlier
-
Zai Lab pauses regulatory filing for bemarituzumab after trial results
-
AMGEN plans $600 million science center at California headquarters
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $342 at Piper Sandler
-
FDA expands AMGEN's Repatha approval for cardiovascular risk reduction
-
Amgen (AMGN) PT Lowered to $335 at Bernstein Amid MariTide Risk
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $330 at RBC Capital on 'Solid Beat And Raise'
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital: 'Strong Print Sets Amgen (AMGN) Shares Back on Track'
-
Amgen (AMGN) Tops Q2 EPS by 76c, Offers Guidance
-
Amgen (AMGN) call put ratio 2.3 calls to 1 put into quarter results
